Head-and-Neck Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The primary site, the origin site, determines how a particular head and neck cancer behaves. The most common type of cancer in the head and neck is squamous cell carcinoma, which arises from the cells that line the inside of the nose, mouth, and throat. Squamous cell carcinoma (HPV) is frequently linked to smoking history or human papilloma virus exposure. In 2017, 890 000 new cases of head and neck cancers (HNCs) [lip and oral cavity (LOC), nasopharynx, other pharynx, and larynx] were reported globally, which is 5. 3% of all cancers, excluding skin cancers other than melanoma, are cancers of the skin. Head and neck cancer may be treated with surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, or a combination of therapies. Surgery is preferred for the majority of patients with early-stage or localized disease.

Description

A head and neck cancer's primary site, or origin site, determines how it will behave. The most common type of cancer in the head and neck is squamous cell carcinoma, which arises from the cells that line the interior of the nose, mouth, and throat. Squamous cell carcinoma (HPV) is frequently linked to exposure to the human papilloma virus or a history of smoking. A few more or less typical types of head and neck cancer include salivary gland tumors, lymphomas, and sarcomas. Avoiding alcohol and tobacco use, immunizing children and teenagers against HPV, and quitting smoking are all ways to ward off the illness. There are four main ways that cancer spreads. The first is a direct expansion of the primary site to nearby locations. The second is spread to lymph nodes by the lymphatic system. The third diffuses (perineural spread) down nerves to different regions of the head and neck. The fourth travels through the blood vessels to distant parts of the body. Head and neck cancer often spreads to the lymph nodes in the neck. The lymph nodes that are frequently affected depend on where the primary tumor originated. The majority of lymph nodes are situated along significant blood vessels and behind the sternocleidomastoid muscle on either side of the neck. Risk factors for bloodstream metastasis to other parts of the body include whether the cancer has spread to the neck lymph nodes, how many nodes are involved, and where in the neck they are situated. The risk is raised if cancer spreads to the lymph nodes in the lower neck as well as the upper neck.

Head-and-Neck Cancer (Epidemiology)

According to the Global Burden of Disease (GBD) study, 890 000 new cases of head and neck cancers (HNCs) [lip and oral cavity (LOC), nasopharynx, other pharynx, and larynx] were reported globally in 2017. 3% of all cancers, excluding skin cancers other than melanoma, are cancers of the skin. The two most common among them were cancers of the larynx and LOC. In total, HNCs resulted in 507000 deaths, or 5.3% of all cancer-related deaths. The incidence of nasal cancer decreased [annual percentage change (EAPC) 1.52, 95% confidence interval (CI), and 1.70 to 1.34), but the incidence of other pharyngeal cancers increased (EAPC 0). Interval of confidence at 95%: 0%, 62. 54-0. 71). LOC cancers were more common (EAPC 0). 26, 95% confidence interval - 0. 16-0. 37), but with observable differences: East Asia had the highest EAPC; men's EAPC decreased in nations with high sociodemographic levels; women's EAPC was higher than men's; and the population aged 15 to 49 years had a higher EAPC than the population aged 50 to 69 years. Less frequently, laryngeal cancer developed. For every 100,000 people in 2017, there were 4 age-standardized incidence rates (ASIR). 84 cases of LOC cancer, 1 nasopharyngeal cancer, 35, 2 additional pharyngeal cancer cases, 19 cases, and 2 cases of pharyngeal cancer. Laryngeal cancer cases total 59. Men still have significantly higher ASIRs than women despite this: 5. Laryngeal cancer risk is 75 times higher than pharyngeal cancer risk, which is about three times higher, according to the ASIR, which is 1. For LOC cancers, men have a 7-fold higher risk than women.

Head-and-Neck Cancer -Current Market Size & Forecast Trends

The market for head-and-neck cancer is projected to grow significantly, with estimates indicating a value of approximately USD 3.25 billion in 2023, expected to reach around USD 7.28 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.6% during this period. The growth is driven by advancements in targeted therapies and immunotherapy, alongside increased investments in innovative surgical procedures and radiation therapies aimed at improving patient outcomes and quality of life. North America is anticipated to dominate the market due to its advanced healthcare infrastructure, while the Asia-Pacific region is expected to grow rapidly due to rising awareness and healthcare access. Overall, the head-and-neck cancer market is well-positioned for robust expansion through 2035 as new therapies and diagnostic technologies continue to emerge.

Surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, or combination therapy may be used to treat head and neck cancer. Surgery is the preferred option for most patients with early or localized disease. Locally occurring diseases can also be taken into account. Depending on the response to first-line therapy, a small number of patients with advanced or metastatic disease may undergo surgical resection of the primary tumor. However, due to their anatomical location and radiosensitivity, nasopharyngeal tumors have very limited or no role for surgery at the site of primary disease. Surgical resection or definitive radiotherapy is the main treatment for oropharyngeal cancer. Surgery is the treatment of choice, except in some patients who may have early tumors of the soft palate, posterior deltoid, and labia. Radiotherapy is preferred for patients who cannot tolerate surgery. For patients for whom surgery alone is not appropriate, alternative treatments include definitive radiotherapy, monotherapy or postoperative chemotherapy, and concurrent chemotherapy followed by induction therapy. For locally advanced diseases, surgery should be considered. Combination chemotherapy is currently the gold standard of care for patients with locally advanced squamous cell carcinoma of the head and neck. Induction chemotherapy is often prescribed to patients with stage III IVB disease before surgery or radiation therapy to shrink and reduce the size of the primary tumor. Patients with stage II-IVB nasopharyngeal carcinoma are treated with concurrent chemotherapy and radiotherapy, adjuvant chemotherapy, or induction chemotherapy followed by concomitant chemotherapy.

Report Highlights

Head-and-Neck Cancer - Current Market Trends

Head-and-Neck Cancer - Current & Forecasted Cases across the G8 Countries

Head-and-Neck Cancer - Market Opportunities and Sales Potential for Agents

Head-and-Neck Cancer - Patient-based Market Forecast to 2035

Head-and-Neck Cancer - Untapped Business Opportunities

Head-and-Neck Cancer - Product Positioning Vis-a-vis Competitors' Products

Head-and-Neck Cancer - KOLs Insight